ANI Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) approval for the Abbreviated New Drug Application (ANDA) for Clorazepate Dipotassium Tablets.
ANI’s Clorazepate Dipotassium Tablets are the generic version of the Reference Listed Drug (RLD) Tranxene®. The current annual U.S. market for Clorazepate Dipotassium Tablets is approximately $25.8M, according to IQVIA/IMS Health, a leading healthcare data and analytics provider.
ANI Pharmaceuticals develops, manufactures, and markets high quality branded and generic prescription pharmaceutical products, including for diseases with high unmet medical need.
For more information, see www.anipharmaceuticals.com.